SAN DIEGO, Sept. 20, 2023 /PRNewswire/ — Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”), a clinical-stage biopharmaceutical company focused on developing liquid drug products containing therapeutic gases, today announced the award of an approximately $3 million Phase 2b SBIR grant from…